First Patient Enrolled in Point Therapeutics' Second Phase 3 Clinical Trial in Metastatic Non-Small Cell Lung Cancer
February 08 2006 - 7:41AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) announced today that it
enrolled the first patient in the company's second Phase 3 clinical
trial, which will evaluate talabostat in combination with
pemetrexed versus pemetrexed with placebo in patients with
metastatic non-small cell lung cancer (NSCLC). This newly initiated
Phase 3 trial is being conducted as part of a Phase 3 clinical
program in NSCLC consisting of two randomized, double blind placebo
controlled trials in up to 800 patients at approximately 100 sites
in North America. The first 400-patient trial, evaluating the
combination of talabostat with docetaxel versus docetaxel and
placebo, has already opened to enrollment. "Initiating patient
enrollment in our second Phase 3 trial is an important milestone
for talabostat's development and the company overall," said Don
Kiepert, President and CEO of Point Therapeutics, Inc. "We are
excited about studying talabostat in our two Phase 3 trials in
metastatic non-small cell lung cancer patients who have failed at
least one prior course of chemotherapy," concluded Kiepert. The
company decided to pursue the Phase 3 program based upon positive
data resulting from the Phase 2 trial in metastatic NSCLC. In the
Phase 2 study combining talabostat with docetaxel, the total number
of observed clinical responses is six, for an overall response rate
of 14.3%. Of the six responding patients, two experienced complete
responses. In addition, of the first 40 patients enrolled in the
study, 48% have survived for at least 12 months. The Phase 3
program was initiated in October 2005. The primary study endpoint
is progression-free survival. Secondary endpoints include overall
survival, objective response rate, duration of response and quality
of life. Trial results for both studies are projected for late
2007. According to the American Cancer Society, lung cancer is the
leading cause of cancer death among men and women in the United
States with nearly 60% of people diagnosed dying within one year
and nearly 75% dying within two years. Nearly all lung cancers are
non-small cell. While treatment options for NSCLC continue to
emerge, mortality rates have not improved in the last 10 years,
leaving a significant need for advancement in current therapies.
About Point Therapeutics, Inc.: Point is a Boston-based
biopharmaceutical company developing a portfolio of dipeptidyl
peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and
as vaccine adjuvants. Point is currently studying its lead product
candidate, talabostat, in two Phase 3 trials in NSCLC. Point is
also studying talabostat in several Phase 2 trials, including as a
single-agent in metastatic melanoma, in combination with cisplatin
in metastatic melanoma, in combination with rituximab in advanced
chronic lymphocytic leukemia, and in combination with gemcitabine
in metastatic pancreatic cancer. In addition, Point's portfolio
includes two other DPP inhibitors in preclinical
development--PT-630 for type 2 diabetes, and PT-510 as a vaccine
adjuvant. Certain statements contained herein are not strictly
historical and are "forward looking" statements as defined in the
Private Securities Litigation Reform Act of 1995. This information
includes statements with respect to the company's clinical
development programs and the timing of initiation and completion of
its clinical trials. Forward-looking statements are statements that
are not historical facts, and can be identified by, among other
things, the use of forward-looking language, such as "believes,"
"feels," "expects," "may," "will," "should," "seeks," "plans,"
"schedule to," "anticipates" or "intends" or the negative of those
terms, or other variations of those terms of comparable language,
or by discussions of strategy or intentions. A number of important
factors could cause actual results to differ materially from those
projected or suggested in the forward looking statement, including
the risk factors described in Point's quarterly report on Form 10-Q
for the quarter ended September 30, 2005 and from time to time in
Point's periodic and other reports filed with the Securities and
Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics News Articles